Vimarsana
Biggest News Aggregation in the World

Page 2 - Roberta Hauser News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Roberta Hauser. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Roberta Hauser Today - Breaking & Trending Today

Novel Wrinkle on Botulinum Toxin Succeeds for Cervical Dystonia - Vimarsana News

Novel Wrinkle on Botulinum Toxin Succeeds for Cervical Dystonia

Formulated for longer activity, symptoms stay suppressed until time for next dose

Pharma Two B Announces Positive Topline Results from its Pivotal Phase III Study of P2B001 in Early Parkinson's Disease - Vimarsana News

Pharma Two B Announces Positive Topline Results from its Pivotal Phase III Study of P2B001 in Early Parkinson's Disease

/PRNewswire/ -- Pharma Two B Ltd., a privately held company developing innovative therapeutics based on reformulation and combinations of previously approved...

Pharma Two B Announces Positive Topline Results from its Pivotal Phase III Study of P2B001 in Early Parkinson's Disease - Vimarsana News

Pharma Two B Announces Positive Topline Results from its Pivotal Phase III Study of P2B001 in Early Parkinson's Disease

/PRNewswire/ -- Pharma Two B Ltd., a privately held company developing innovative therapeutics based on reformulation and combinations of previously approved...

Pharma Two B Announces Positive Topline Results from its Pivotal Phase III Study of P2B001 in Early Parkinson's Disease - Vimarsana News

Pharma Two B Announces Positive Topline Results from its Pivotal Phase III Study of P2B001 in Early Parkinson's Disease

/PRNewswire/ -- Pharma Two B Ltd., a privately held company developing innovative therapeutics based on reformulation and combinations of previously approved...

Pharma Two B Ltd.: Pharma Two B Announces Positive Topline Results from its Pivotal Phase III Study of P2B001 in Early Parkinson's Disease - Vimarsana News

Pharma Two B Ltd.: Pharma Two B Announces Positive Topline Results from its Pivotal Phase III Study of P2B001 in Early Parkinson's Disease

Study successfully met its primary and key secondary endpoints, demonstrating superior efficacy of P2B001 compared to its individual components P2B001 showed comparable efficacy to a marketed